Key result
Blebbistatin decreased the steady-state actin-activated ATPase activity of NMIIB S1 by approximately 90% at 40 microM actin, primarily by blocking entry into the strong binding state.
Population
Nonmuscle myosin IIB subfragment 1 (NMIIB S1)
Comparison
Blebbistatin vs Absence of blebbistatin
Design
Preclinical
Authors
Loading...
May guide myosin II inhibitor development; leaves open translation to cardiovascular models.
Blebbistatin inhibits nonmuscle myosin IIB ATPase activity by blocking entry into the strong binding state and reducing ADP release rate.
Ramamurthy et al. (2004) studied this question. Blebbistatin was evaluated on Steady-state actin-activated ATPase activity of NMIIB S1. Blebbistatin decreased the steady-state actin-activated ATPase activity of NMIIB S1 by approximately 90% at 40 microM actin, primarily by blocking entry into the strong binding state.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: